Clinical Trials

Title   [606906-11] A Randomized Phase II Trial of Ipilimumab with or without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma
Description   This randomized phase II trial studies how well ipilimumab with or without bevacizumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Monoclonal antibodies, such as ipilimumab and bevacizumab, block tumor growth in different ways by targeting certain cells.
IRB Number   14-142
Treatment   Oncology - Melanoma
Status   Active
Principal Name   Thomas Butler, M.D.
Contact Name   Kathleen Ollis

Email Newsletters

Connect With Us